Felipe Vences-Catalan
Overview
Explore the profile of Felipe Vences-Catalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vences-Catalan F, Levy S
Trends Cell Biol
. 2021 Dec;
32(5):377-379.
PMID: 34865939
Tetraspanins mark stem cells and tumor initiating cells. Recent studies in adipose development, intestinal crypt remodeling, and muscle stem cells shed new light on the contribution of tetraspanins and their...
2.
Kamber R, Nishiga Y, Morton B, Banuelos A, Barkal A, Vences-Catalan F, et al.
Nature
. 2021 Sep;
597(7877):549-554.
PMID: 34497417
Monoclonal antibody therapies targeting tumour antigens drive cancer cell elimination in large part by triggering macrophage phagocytosis of cancer cells. However, cancer cells evade phagocytosis using mechanisms that are incompletely...
3.
Vences-Catalan F, Rajapaksa R, Kuo C, Miller C, Lee A, Ramani V, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(24).
PMID: 34099563
Tetraspanins are an evolutionary conserved family of proteins involved in multiple aspects of cell physiology, including proliferation, migration and invasion, protein trafficking, and signal transduction; yet their detailed mechanism of...
4.
Vences-Catalan F, Kuo C, Rajapaksa R, Duault C, Andor N, Czerwinski D, et al.
J Exp Med
. 2019 May;
216(7):1497-1508.
PMID: 31123084
The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that...
5.
Ramachandran R, Vences-Catalan F, Wiseman D, Zlotkin-Rivkin E, Shteyer E, Melamed-Book N, et al.
Infect Immun
. 2018 Jul;
86(10).
PMID: 30037792
Enteropathogenic (EPEC) belongs to a group of enteric human pathogens known as attaching-and-effacing (A/E) pathogens, which utilize a type III secretion system (T3SS) to translocate a battery of effector proteins...
6.
Vences-Catalan F, Levy S
Front Immunol
. 2018 Jun;
9:1277.
PMID: 29946318
Metastasis is the ultimate consequence of cancer progression and the cause of patients' death across different cancer types. Patients with initial diagnosis of distant disease have a worst 5-year survival...
7.
Hebb J, Mosley A, Vences-Catalan F, Rajasekaran N, Rosen A, Ellmark P, et al.
Cancer Immunol Immunother
. 2017 Sep;
67(1):47-60.
PMID: 28905118
The delivery of immunomodulators directly into the tumor potentially harnesses the existing antigen, tumor-specific infiltrating lymphocytes, and antigen presenting cells. This can confer specificity and generate a potent systemic anti-tumor...
8.
Rocha-Perugini V, Suarez H, Alvarez S, Lopez-Martin S, Lenzi G, Vences-Catalan F, et al.
Nat Microbiol
. 2017 Sep;
2(11):1513-1522.
PMID: 28871089
In this study, we report that the tetraspanin CD81 enhances human immunodeficiency virus (HIV)-1 reverse transcription in HIV-1-infected cells. This is enabled by the direct interaction of CD81 with the...
9.
Vences-Catalan F, Duault C, Kuo C, Rajapaksa R, Levy R, Levy S
Biochem Soc Trans
. 2017 Apr;
45(2):531-535.
PMID: 28408492
CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell-cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering...
10.
Vences-Catalan F, Rajapaksa R, Srivastava M, Marabelle A, Kuo C, Levy R, et al.
Oncoimmunology
. 2016 Jul;
5(5):e1120399.
PMID: 27467918
Cancer cells can escape the antitumor immune response by recruiting immune suppressor cells. However, although innate myeloid-derived suppressor cells (MDSCs) and T regulatory (Treg) cells accumulate normally in tumor-bearing CD81-deficient...